Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non-Randomized Phase II Study of Neoadjuvant Camrelizumab Combined With Paclitaxel and Carboplatin in Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity and Larynx (Stage III-IVA)

NCT07400094 is registered in ClinicalTrials.gov with National Medical Research Radiological Centre of the Ministry of Health of Russia as lead sponsor.

NCT NCT07400094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07400094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non-Randomized Phase II Study of Neoadjuvant Camrelizumab Combined With Paclitaxel and Carboplatin in Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity and Larynx (Stage III-IVA)
Lead sponsor
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 28, 2026
Completion date
February 28, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

laryngeal neoplasms, oral cavity neoplasm, squamous cell carcinoma of head and neck